Document is current
Any future updates will be listed below
-
Authors
Liu, Han-Yuan http://orcid.org/0000-0002-9398-6969
Li, Zhengnian
Reindl, Theresia http://orcid.org/0000-0001-9633-1899
He, Zhixiang
Qiu, Xueer
Golden, Ryan P. http://orcid.org/0009-0004-7113-007X
Donovan, Katherine A. http://orcid.org/0000-0002-8539-5106
Bailey, Adam
Fischer, Eric S. http://orcid.org/0000-0001-7337-6306
Zhang, Tinghu
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Yang, Priscilla L. http://orcid.org/0000-0001-7456-2557
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01AI48632, R01AI146152)
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 18 January 2024
Accepted: 23 May 2024
First Online: 19 June 2024
Competing interests
: N.S.G is a founder, science advisory board member (SAB) and equity holder in Syros, C4, Allorion, Lighthorse, Voronoi, Inception, Matchpoint, CobroVentures, GSK, Shenandoah (board member), Larkspur (board member) and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. E.S.F. is a founder, member of the scientific advisory board (SAB), and equity holder of Civetta Therapeutics, Lighthorse, Proximity Therapeutics, and Neomorph Inc (also board of directors), SAB member and equity holder in Avilar Therapeutics and Photys Therapeutics, and a consultant to Astellas, Sanofi, Novartis, Deerfield, Ajax and EcoR1 capital. The Fischer laboratory receives or has received research funding from Novartis, Deerfield, Ajax, Interline, and Astellas. K.A.D receives or has received consulting fees from Kronos Bio and Neomorph Inc. T.Z. is a scientific founder, equity holder, and consultant of Matchpoint, equity holder of Shenandoah. H.L. is currently an employee of Amgen. The remaining authors declare no competing interests.
